$45.38
0.79% yesterday
NYSE, Sep 27, 09:48 pm CET
ISIN
NL0012169213
Symbol
QGEN

QIAGEN NV Stock price

$45.24
-0.78 1.69% 1M
+2.49 5.82% 6M
+0.47 1.04% YTD
+4.55 11.18% 1Y
-9.03 16.64% 3Y
+11.37 33.59% 5Y
+20.63 83.81% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.22 0.49%
ISIN
NL0012169213
Symbol
QGEN
Sector

Key metrics

Market capitalization $9.99b
Enterprise Value $10.50b
P/E (TTM) P/E ratio 143.47
EV/FCF (TTM) EV/FCF 25.39
EV/Sales (TTM) EV/Sales 5.41
P/S ratio (TTM) P/S ratio 5.15
P/B ratio (TTM) P/B ratio 2.94
Revenue growth (TTM) Revenue growth -1.90%
Revenue (TTM) Revenue $1.94b
EBIT (operating result TTM) EBIT $449.75m
Free Cash Flow (TTM) Free Cash Flow $413.58m
Cash position $890.24m
EPS (TTM) EPS $0.31
P/E forward 91.68
P/S forward 5.06
EV/Sales forward 5.32
Short interest 1.75%
Show more

Is QIAGEN NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

QIAGEN NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a QIAGEN NV forecast:

13x Buy
62%
8x Hold
38%

Analyst Opinions

21 Analysts have issued a QIAGEN NV forecast:

Buy
62%
Hold
38%

Financial data from QIAGEN NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,940 1,940
2% 2%
100%
- Direct Costs 728 728
1% 1%
38%
1,212 1,212
3% 3%
62%
- Selling and Administrative Expenses 358 358
7% 7%
18%
- Research and Development Expense 194 194
2% 2%
10%
660 660
0% 0%
34%
- Depreciation and Amortization 210 210
1% 1%
11%
EBIT (Operating Income) EBIT 450 450
1% 1%
23%
Net Profit 73 73
78% 78%
4%

In millions USD.

Don't miss a Thing! We will send you all news about QIAGEN NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

QIAGEN NV Stock News

Neutral
GlobeNewsWire
one day ago
Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN's devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to transition over 180 products to new IVDR regulatory ...
Neutral
GlobeNewsWire
2 days ago
PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important...
Neutral
GlobeNewsWire
4 days ago
QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide // Partnership builds on QIAGEN's leading global po...
More QIAGEN NV News

Company Profile

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Head office Netherlands
CEO Thierry Bernard
Employees 5,967
Founded 1996
Website www.qiagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today